1. Although different types of the polymer PLGA may be used, a higher encapsulation efficiency of the enzyme is obtained with the PLGA Resomer 503H (with free carboxyl-end groups).

2. The organic solvent used to dissolve the polymer, ethyl acetate, has been reported to maintain L-asparaginase activity. Moreover, the loss of enzyme activity has been shown to be dependent on the initial concentration of the enzyme. At higher concentrations the activity is better preserved.

3. The sonication energy used in this step is gentle enough to preserve enzyme activity.

4. Different lipids and methods can be used for the preparation of enzyme-containing liposomes. However, the encapsulation efficiency, enzymatic activity, and protein-to-lipid ratio are found to be highly dependent on the lipid composition used.

a. If dicetyl phosphate is used, a loss of enzymatic activity is observed.

b. The addition of stearylamine increases the encapsulation efficiency up to 100%, with only a mild loss of enzymatic activity.

c. Low-encapsulation efficiencies are observed with lipid mixtures of dimyristoyl-phosphatidylcholine (DMPC) with dioleoyl-phosphatidylcholine (DOPC).

5. The temperature of the aqueous phase must be higher than the main lamellar chain-melting phase transition temperature (Tm) of the phospholipid mixture.

6. The use of 0.3 M mannitol instead of deionized water in the rehydration step leads to an improved recovery, since it maintains a physiological intraliposomal osmolarity.

7. As an alternative of DRV liposomes, VET (extruded vesicles) liposomes can be made, although the encapsulation efficiency of the latter is much lower.


1. Liang, J. F., Li, Y. T., and Yang, V. V. (2000) Biomedical application of immobilized enzymes. J. Pharm. Sci. 89, 979-990.

2. Torchilin, V. P. (1987) Immobilised enzymes as drugs. Adv. Drug Del. Rev. 1, 41-86.

3. Lizano, C., Pérez, M. T., and Pinilla, M. (2001) Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation: in vivo survival rate in circulation, organ distribution and ethanol degradation. Life Sci. 68, 2001-2016.

4. Lizano, C., Sanz, S., Luque, J., and Pinilla. M. (1998) In vitro study of alcohol dehydrogenase and acetaldehyde dehydrogenase encapsulated into human erythrocytes by an electroporation procedure. BBA—Gen. Subjects 1425, 328-336.

5. Gaspar, M. M., Blanco, D., Cruz, M. E. M., and Alonso, M. J. (1998)Formulation of L-asparaginase-loaded poly(lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release. J. Control. Rel. 52, 53-62.

6. Cruz, M. E. M., Gaspar, M. M., Lopes, F., Jorge, J. S., and Perez-Soler, R. (1993) Liposomal L-asparaginase: in vitro evaluation. Int. J. Pharm. 96, 67-77.

7. Avrami, V. I., Sencer, S., Periclou, A. P., et al. (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children's cancer group study. Blood 99, 1986-1994.

8. Balcao, V. M., Mateo, C., Fernández-Lafuente, R., Malcasa, F. X., and Guisán, J. M. (2001) Structural and functional stabilization of L-asparaginase via multisubunit immobilization onto highly activated supports. Biotechnol. Prog. 17, 537-542.

9. Hershfield, M. (1995) PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin. Immunol. Immunopathol. 76, 228-232.

10. Ensor, C. M., Bomalaski, J. S., and Clark, M. A. (2002) PEGylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 62, 5443-5450.

11. Lohr, M., Hummel, F., Faulmann, G., et al. (2002) Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century. Cancer Chemother. Pharmacol. 49, S21-S24.

12. Belchetz, P. E., Crawley, J. C. W., Braidman, I. P., and Gregoriadis, G. (1977) Treatment of Gaucher's disease with liposome-entrapped glucocerebroside: P-glucosidase. Lancet 310, 116-117.

13. Korablyov, V., Zimran, A., and Barenholz, Y. (1999) Cerebroside-P-glucosidase encapsulation in liposomes for Gaucher's disease treatment revisited. Pharm. Res. 16, 466-469.

14. Storm, G., Vingerhoeds, M. H., Crommelin, D. J. A., and Haisma, H. J. (1997) Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs. Adv. Drug Del. Rev. 24, 225-231.

15. Hill, K. J., Kaszuba, M., Creeth, J. E., and Jones, M. N. (1997). Reactive liposomes encapsulating a glucose oxidase-peroxidase system with antibacterial activity. BBA - Biomembranes 1326, 37-46.

16. Genta, I., Perugini, P., Pavanetto, F., et al. (2001) Conti Enzyme loaded biodegradable microspheres in vitro: ex vivo evaluation. J. Control. Rel. 77, 287-295.

17. Storm, G., Koppenhagen, F., Heeremans, A., Vingerhoeds, M., Woodle, M. C., and Crommelin, D. J. A. Novel developments in liposomal delivery of peptides and proteins. J. Control. Rel. 36, 19-24.

18. Santini, B., Antonelli, M., Battistini, A., et al. (2000) Comparison of two enteric coated microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis. Digest. Liver Dis. 32, 406-411.

19. Patchell, C. J., Desai, M., Weller, P. H., et al. (2002) Creon® 10000 Minimicro-spheres™ vs. Creon® 8000 microspheres—an open randomised crossover preference study. J. Cystic Fibrosis 4, 287-291.

20. Petrikovics, I., Hong, K., Omburo, G., et al. (1999) Antagonism of paraoxon intoxication by recombinant phosphotriesterase encapsulated within sterically stabilized liposomes. Toxicol. Appl. Pharm. 156, 56-63.

21. Chang, T. M. S., Bourget, L., and Lister, C. (1995) A new theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme artificial cells, as in removing phenylalanine in phenylketo-nuria. Art. Cells Blood Subs. Immob. Biotech. 23, 1-21.

22. Bourget, L. and Chang, T. M. S. (1985) Phenylalanine ammonia-lyase immobilized in semipermeable microcapsules for enzyme replacement in phenylketonuria. FEBS Lett. 180, 5-8.

23. Liang, J. F., Li, Y. T., and Yang, V. C. (2000) A novel approach for delivery of enzyme drugs: preliminary demonstration of feasibility and utility in vitro. Int. J. Pharm. 202, 11-20.

24. Wolfe, E. A. and Chang T. M. S. (1987) Orally ingested microencapsulated urease and an adsorbent, zirconium phosphate, to remove urea in kidney failure. Int. J. Artif. Org. 10, 269-274.

25. Prakash, S. and Chang, T. M. S. (1996) Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat. Med. 2, 883-887.

26. Tischer, W. and Kasche, V. (1999) Immobilized enzymes: crystals or carriers? Trends Biotechnol. 17, 326-335.

27. Vina, I., Karsakevich, A., and Bekers, M. (2001) Stabilization of anti-leukemic enzyme L-asparaginase by immobilization on polysaccharide levan. J. Mol. Catal. B: Enzym. 11, 551-558.

28. Roberts, M. J., Bentley, M. D., and Harris, J. M. (2002) Chemistry for Peptide and Protein PEGylation. Adv. Drug Deliv. Rev. 54, 459-476.

29. Kodera, Y., Matsushima, A., Hiroto, M., et al. (1998) Pegylation of proteins and bioactive substances for medical and technical applications. Prog. Polym. Sci. 23, 1233-1271.

30. Vellard, M. (2003) The enzyme as drug: application of enzymes as pharmaceuticals. Curr. Opin. Biotech. 14, 444-450.

31. Neerunjun, E. F. and Gregoriadis, G. (1976) Tumor regression with liposome-en-trapped asparaginase: some immunological advantages. Biochem. Soc. T. 4, 133134.

32. Panyam, J. and Labhasetwar, V. (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Del. Rev. 55, 329-347.

33. Graham, M. L. (2003) Pegaspargase: a review of clinical studies. Adv. Drug Del. Rev. 55, 1293-1302.

34. Müller, H. J. and Boos, J. (1998) Use of L-asparaginase in childhood ALL. Crit. Rev. Oncol. Hemat. 28, 97-113.

35. Duval, M., Suciu, S.,Ferster, A., et al. (2002) Comparison of Escherichia coli-aspara-ginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer—Children's Leukemia Group phase 3 trial. Blood 99, 2734-2739.

36. Alvarez, O. A. and Zimmerman, G. (2000) Pegaspargase-induced pancreatitis. MedPediatr. Oncol. 34, 200-205.

37. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951)Protein measurement with the Folin Phenol reagent. J. Biol. Chem. 193, 265-275

38. Jayaram, H. N., Cooney, D. A., and Jayaram, S. (1974) A simple and rapid method for the estimation of L-asparaginase in chromatographic and electrophoretic effluents: comparison with other methods. Anal. Biochem. 59, 327-346.

39. Rouser, G., Flusher, S., and Yamamoto, A. (1970) Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5, 494-496.

Was this article helpful?

0 0
Detoxify the Body

Detoxify the Body

Need to Detoxify? Discover The Secrets to Detox Your Body The Quick & Easy Way at Home! Too much partying got you feeling bad about yourself? Or perhaps you want to lose weight and have tried everything under the sun?

Get My Free Ebook

Post a comment